Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody–Drug Conjugates (ADCs)
Current Ophthalmology Reports · 25.03.2024 · 12 (2) · 13-22
DOI: 10.1007/s40135-024-00322-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Ophthalmology Reports, online erschienen am 25.03.2024. Verfasst von Ethan S Lindgren und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NCI NIH HHS, National Eye Institute.
Abstract (Originalsprache)
Purpose of Review This study is to highlight the incidence of corneal pseudomicrocysts in FDA-approved antibody–drug conjugates (ADCs), and success of preventive therapies for pseudomicrocysts and related ocular surface adverse events (AEs). Recent Findings ADCs are an emerging class of selective cancer therapies that consist of a potent cytotoxin connected to a monoclonal antibody (mAb) that targets antigens expressed on malignant cells. Currently, there are 11 FDA-approved ADCs with over 164 in clinical trials. Various AEs have been attributed to ADCs, including ocular surface AEs (keratitis/keratopathy, dry eye, conjunctivitis, blurred vision, corneal pseudomicrocysts). While the severity and prevalence of ADC-induced ocular surface AEs are well reported, the reporting of corneal pseudomicrocysts is limited, complicating the development of therapies to prevent or treat ADC-related ocular surface toxicity. Summary Three of 11 FDA-approved ADCs have been implicated with corneal pseudomicrocysts, with incidence ranging from 41 to 100% of patients. Of the six ADCs that reported ocular surface AEs, only three had ocular substudies to investigate the benefit of preventive therapies including topical steroids, vasoconstrictors, and preservative-free lubricants. Current preventive therapies demonstrate limited efficacy at mitigating pseudomicrocysts and other ocular surface AEs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.
- Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
- Departments of Medicine and Physiology, University of California San Francisco, San Francisco, CA, USA.
- Francis I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.
- Department of Ophthalmology and Visual Science, University of Chicago Medical Center, Chicago, IL, USA.
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Förderung
- NEI NIH HHS
- NCI NIH HHS
- National Eye Institute
- Research to Prevent Blindness
- All May See Foundation
Zitieren
APA
Lindgren, E. S., Yan, R., Cil, O., Verkman, A. S., Chan, M. F., Seitzman, G. D., Farooq, A. V., Huppert, L. A., Rugo, H. S., Pohlmann, P. R., Lu, J., Esserman, L. J., & Pasricha, N. D. (2024). Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody–Drug Conjugates (ADCs). Current Ophthalmology Reports, 12(2), 13-22. https://doi.org/10.1007/s40135-024-00322-5
Vancouver
Lindgren ES, Yan R, Cil O, Verkman AS, Chan MF, Seitzman GD, et al. Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody–Drug Conjugates (ADCs). Current Ophthalmology Reports. 2024;12(2):13-22. doi:10.1007/s40135-024-00322-5
BibTeX
@article{Lindgren2024,
author = {Lindgren, Ethan S and Yan, Rongshan and Cil, Onur and Verkman, Alan S and Chan, Matilda F and Seitzman, Gerami D and Farooq, Asim V and Huppert, Laura A and Rugo, Hope S and Pohlmann, Paula R and Lu, Janice and Esserman, Laura J and Pasricha, Neel D},
title = {Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody–Drug Conjugates (ADCs)},
journal = {Current Ophthalmology Reports},
year = {2024},
volume = {12},
number = {2},
pages = {13--22},
doi = {10.1007/s40135-024-00322-5}
}
EUVIMED